Foldax announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday.

Foldax announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial of the TRIATM biopolymer surgical aortic heart valve.

Foldax announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio

Foldax Appoints Scott Huennekens to Board of Directors

Publication in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions Found TRIA Aortic Heart Valve Provided Sustained Improvement in Heart Valve Function to One-Year with Good Safety Profile

Foldax announces that the Drugs Controller General of India (DCGI) has approved initiation of a clinical trial of the TRIA™ biopolymer surgical aortic heart valve.

Foldax®, Inc. announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve.